| 66.03 -0.52 (-0.78%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 84.42 |
1-year : | 89 |
| Resists | First : | 72.28 |
Second : | 76.19 |
| Pivot price | 71.09 |
|||
| Supports | First : | 65.94 |
Second : | 54.86 |
| MAs | MA(5) : | 68.12 |
MA(20) : | 71.69 |
| MA(100) : | 69.11 |
MA(250) : | 74.29 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 1.3 |
D(3) : | 2 |
| RSI | RSI(14): 28.8 |
|||
| 52-week | High : | 87.21 | Low : | 61.83 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALC ] has closed below the lower bollinger band by 3.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ALC ] is to continue within current trading range. Bollinger Bands are 23.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 67.85 - 68.5 | 68.5 - 68.9 |
| Low: | 64.55 - 65.4 | 65.4 - 65.92 |
| Close: | 65.06 - 66.44 | 66.44 - 67.27 |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Mon, 07 Sep 2026
Alcon Inc. (ALC) Stock Analysis: Exploring A Promising 20.91% Upside Potential - DirectorsTalk Interviews
Thu, 03 Sep 2026
Alcon: A Re-Rating In Eyesight - Seeking Alpha
Thu, 03 Sep 2026
Are Options Traders Betting on a Big Move in Alcon Stock? - TradingView
Thu, 03 Sep 2026
Eye surgeons get a viewing zone up to six times larger from Alcon's new microscope. - Stock Titan
Mon, 31 Aug 2026
Alcon Inc. (ALC) Stock Analysis: A Closer Look At Its 18.37% Potential Upside - DirectorsTalk Interviews
Sat, 29 Aug 2026
Precision Trading with Alcon Inc. (ALC) Risk Zones - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 483 (M) |
| Shares Float | 482 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 66 (%) |
| Shares Short | 13,660 (K) |
| Shares Short P.Month | 13,010 (K) |
| EPS | 1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 44.66 |
| Profit Margin | 5.9 % |
| Operating Margin | 14.6 % |
| Return on Assets (ttm) | 2.7 % |
| Return on Equity (ttm) | 2.9 % |
| Qtrly Rev. Growth | 8.6 % |
| Gross Profit (p.s.) | 12.86 |
| Sales Per Share | 22.46 |
| EBITDA (p.s.) | 4.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2,310 (M) |
| Levered Free Cash Flow | 1,270 (M) |
| PE Ratio | 50.4 |
| PEG Ratio | 1.2 |
| Price to Book value | 1.47 |
| Price to Sales | 2.93 |
| Price to Cash Flow | 13.81 |
| Dividend | 0.36 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|